Cited 0 times in
Early prediction of long-term response to cabergoline in patients with macroprolactinomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이영기 | - |
dc.date.accessioned | 2015-12-24T09:03:23Z | - |
dc.date.available | 2015-12-24T09:03:23Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/134856 | - |
dc.description | Dept. of Medicine/석사 | - |
dc.description.abstract | Cabergoline is effective for treating prolactinomas. However, some patients display cabergoline resistance, and their early characteristics are not well known. We analyzed early indicators predicting the long-term response to cabergoline. We retrospectively reviewed 44 patients with macroprolactinomas who received cabergoline as first-line treatment; the patients were followed-up for a median of 16 months. The influences of various clinical parameters on outcomes were evaluated. Forty patients (90.9%) could be medically treated, displaying tumor volume reduction (TVR) of 74.7%, prolactin normalization (NP) rate of 81.8%, and complete response (CR; TVR>50% with NP, without surgery) rate of 70.5%. Most patients (93.1%) with TVR≥25% and NP at 3 months eventually achieved CR, whereas 50% of patients with TVR≥25% without NP and no patient without TVR≥25% achieved CR. TVR at 3 months was strongly correlated with the final TVR (R=0.785). Patients with large macroadenomas exhibited a low NP rate at 3 months but eventually achieved TVR and NP rates similar to those of patients with smaller tumors. Surgery independently reduced the final dose of cabergoline (β=−1.181 mg/week), and two of four patients who underwent surgery could discontinue cabergoline. Determining cabergoline response using TVR and NP at 3 months after treatment is useful for predicting later outcomes. However, further cabergoline administration should be considered for patients with TVR>25% at 3 months without NP, especially with huge prolactinomas, because a delayed response may be achieved. As surgery can reduce the cabergoline dose with successful disease control, it should be considered for cabergoline-resistant patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.publisher | Graduate School, Yonsei University | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Early prediction of long-term response to cabergoline in patients with macroprolactinomas | - |
dc.title.alternative | 프로락틴 분비 거대선종 환자의 장기적인 카버골린 치료 반응의 초기 예측 지표 | - |
dc.type | Thesis | - |
dc.contributor.alternativeName | Lee, Young ki | - |
dc.type.local | Thesis | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.